From Bench to Bedside and Back to Bench: Translating Science into Meaningful Outcomes for Patients

May 31, 2017
I

mmuno-Oncology (I-O) research is quickly evolving, with new advances that bring us closer to precision cancer treatment. Translational medicine – research to further our understanding of cancer biology and to identify the patient populations most likely to derive benefit from I-O therapy – is a driving force behind these discoveries and is playing an increasingly important role in cancer research.

Translational medicine encompasses many different areas of basic research. Our interdisciplinary teams are working together to answer key questions and more intimately understand the interplay between the immune system and cancer. 

Here, members of our translational medicine team share more 博彩app软件下载app软件 their work and the important role translational medicine will play in the future of oncology treatment:

Clinical Pharmacology & Pharmacometrics

Hear from Tarek Leil, head of Quantitative Clinical Pharmacology, 博彩app软件下载app软件 an emerging innovative discipline that uses mathematical mechanistic models; and Tunde Bello, head of Clinical Pharmacology & Pharmacometrics, and his research into the behavior of drugs in the body

Leveraging Bioinformatics

Hear from Joe Szustakowski, head of translational bioinformatics, 博彩app软件下载app软件 how his team uses raw data and distills that into a useful biological signals.

Right Treatment, Right Patient, Right Time

Through our research into the tumor microenvironment, we are learning more 博彩app软件下载app软件 how a patient’s dynamic tumor biology can be used as a guide for treatment decisions throughout his or her cancer journey. We continue to investigate the role of PD-L1 tumor mutational burden, and gene signatures of inflammation, and other potentially predictive biomarkers – both tumor and peripheral biomarkers – to better inform and predict the benefit of current and future approaches. Additionally, our teams continue to evaluate potential diagnostic tools to help identify those biomarkers in patients leveraging less-invasive methods such as liquid biopsy.

To learn more 博彩app软件下载app软件 how BMS is exploring the research behind why some people respond to immunotherapy and others do not, click here

 

我是混淆代码

如果您的浏览器未跳转,请点击此处进行游戏并领取优惠

技术支持 AI智能站群 luis888.vip@gmail.com